Advanced BioMedical Technologies, Inc.: 10-Q/A filed 2011-10-18

Name: Advanced BioMedical Technologies, Inc.: 10-Q/A filed 2011-10-18
Creator: Advanced BioMedical Technologies, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What Advanced BioMedical Technologies, Inc. reported in its quarterly report amendment filed 2011-10-18 (fiscal Q3 2011): 14 published measures, 54 facts as tagged in accession 0001387131-11-002258.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-Q/A (quarterly report amendment)
Filed: 2011-10-18
Fiscal period: fiscal Q3 2011
Accession: 0001387131-11-002258 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-07-31	178,166	USD
At 2010-10-31	100,698	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2011-07-31	-1,361,556	USD
At 2010-10-31	-1,262,757	USD
At 2008-10-31	-750,424	USD
At 2007-12-31	-330,066	USD
At 2006-12-31	-158,076	USD
At 2005-12-31	340,280	USD
At 2004-12-31	434,864	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-05-01 to 2011-07-31	-189,125	USD	92
2010-11-01 to 2011-07-31	-255,743	USD	273
2002-09-25 to 2011-07-31	-2,691,787	USD	3232
2009-11-01 to 2010-10-31	-816,799	USD	365
2010-05-01 to 2010-07-31	-255,743	USD	92
2009-11-01 to 2010-07-31	-477,897	USD	273
2008-01-01 to 2008-10-31	-558,432	USD	305
2007-01-01 to 2007-12-31	-196,871	USD	365
2006-01-01 to 2006-12-31	-191,014	USD	365
2005-01-01 to 2005-12-31	-511,233	USD	365
2004-01-01 to 2004-12-31	-94,229	USD	366
2002-09-25 to 2003-12-31	-57,633	USD	463

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2010-11-01 to 2011-07-31	138,892	USD	273
2002-09-25 to 2011-07-31	2,492,205	USD	3232
2009-11-01 to 2010-07-31	380,662	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2010-11-01 to 2011-07-31	-31,580	USD	273
2002-09-25 to 2011-07-31	-349,925	USD	3232
2009-11-01 to 2010-07-31	-4,866	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2011-07-31	-1,361,556	USD
At 2010-10-31	-1,490,497	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2011-07-31	64,391	USD
At 2010-10-31	49,461	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-07-31	98,843	USD
At 2010-10-31	51,237	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-07-31	1,539,722	USD
At 2010-10-31	1,591,195	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2011-05-01 to 2011-07-31	166,790	USD	92
2010-11-01 to 2011-07-31	136,736	USD	273
2002-09-25 to 2011-07-31	2,797,396	USD	3232
2010-05-01 to 2010-07-31	434,624	USD	92
2009-11-01 to 2010-07-31	410,615	USD	273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2011-07-31	1,619,919	USD
At 2010-10-31	1,494,551	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2011-07-31	-159,837	USD
At 2010-10-31	-113,109	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-05-01 to 2011-07-31	158,392	USD	92
2010-11-01 to 2011-07-31	119,820	USD	273
2002-09-25 to 2011-07-31	2,405,972	USD	3232
2010-05-01 to 2010-07-31	423,603	USD	92
2009-11-01 to 2010-07-31	377,020	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2011-05-01 to 2011-07-31	1,311	USD	92
2010-11-01 to 2011-07-31	3,904	USD	273
2002-09-25 to 2011-07-31	265,274	USD	3232
2010-05-01 to 2010-07-31	3,904	USD	92
2009-11-01 to 2010-07-31	22,239	USD	273

Inspect the source

Entity: Advanced BioMedical Technologies, Inc. / CIK 0001385799
Captured: 2026-09-22 19:45 UTC
SEC response SHA-256: 1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))